Nephron Pharmaceuticals Corporation v. Hulsey

CourtDistrict Court, M.D. Florida
DecidedMarch 1, 2021
Docket6:18-cv-01573
StatusUnknown

This text of Nephron Pharmaceuticals Corporation v. Hulsey (Nephron Pharmaceuticals Corporation v. Hulsey) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nephron Pharmaceuticals Corporation v. Hulsey, (M.D. Fla. 2021).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA ORLANDO DIVISION

NEPHRON PHARMACEUTICALS CORPORATION, NEPHRON S.C., INC. and NEPHRON STERILE COMPOUNDING CENTER LLC,

Plaintiffs,

v. Case No: 6:18-cv-1573-GAP-LRH

JENNIFER SHELLY HULSEY, U.S. COMPOUNDING INC. and ADAMIS PHARMACEUTICALS CORPORATION,

Defendants.

ORDER This matter comes before the Court on Plaintiffs’ Motion for Order to Show Cause why Defendants should not be adjudged in civil contempt for failure to comply with the Consent Preliminary Injunction (Doc. 129) and the Court’s subsequent Order (Doc. 131). On referral, Magistrate Judge Leslie R. Hoffman issued a Report and Recommendation (Doc. 212) recommending that the Court hold Defendants in civil contempt and grant in part and deny in part the sanctions sought in the Motion. Defendants filed an Objection to the Report (Doc. 216) and Plaintiffs filed a Response (Doc. 220). Upon de novo review of the above, the Report will be confirmed and adopted. I. Background In this case, Plaintiffs Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center LLC (collectively, “Nephron”) claim that Defendant Jennifer Shelly Hulsey (“Hulsey”), a former Nephron employee, misappropriated trade secrets when she was hired by U.S. Compounding Inc. (“USC”). Nephron asserts that USC and its parent company, Adamis Pharmaceuticals Corporation (“Adamis”; collectively, “Defendants”), are liable for directing Hulsey to obtain and provide them with the alleged trade secrets.1 At the outset of this litigation, the parties agreed to a Consent Preliminary Injunction (“CPI”), which the Court entered on October 15, 2018. (Doc. 29). On June 27, 2020, Nephron

filed a Motion for Order to Show Cause (Doc. 129) claiming that Defendants violated the CPI by using Nephron data they acquired from a former Nephron employee, Jessica Lane (“Lane”).2 II. Legal Standards A. Review of Reports and Recommendations In resolving objections to the recommendation of a magistrate judge, the district judge must determine de novo any part of the magistrate judge's disposition that has been properly objected to.3 Fed. R. Civ. P. 72(b)(3). De novo review requires independent consideration of factual issues based on the record. Jeffrey S. ex rel. Ernest S. v. State Bd. of Educ. of Ga., 896 F.2d 507, 513 (11th Cir. 1990). After conducting a careful and complete review of the findings and

recommendations, the district judge “may accept, reject, or modify the recommended disposition; receive further evidence; or return the matter to the magistrate judge with instructions.” Fed. R. Civ. P. 72(b)(3). B. Civil Contempt

1 Nephron’s claims against Hulsey are currently stayed as she has filed for bankruptcy. 2 The Court adopts and incorporates by reference the “Factual Background” section of the Report and Recommendation. (Doc. 212 at 2–6). 3 Where a litigant does not make specific objections to a magistrate judge's factual findings, those findings are reviewed for clear error. Garvey v. Vaughn, 993 F.2d 776, 779 n.9 (11th Cir. 1993). An injunction can be enforced through a contempt proceeding. Doe v. Bush, 261 F.3d 1037, 1064 (11th Cir. 2001). A finding of civil contempt must be supported by clear and convincing evidence. McGregor v. Chierico, 206 F.3d 1378, 1383 (11th Cir. 2000). “The clear and convincing evidence must establish that: (1) the allegedly violated order was valid and lawful; (2) the order was clear and unambiguous; and (3) the alleged violator had the ability to comply with

the order.” Id. “In determining whether a party is in contempt of a court order, the order is subject to reasonable interpretation, though it may not be expanded beyond the meaning of its terms absent notice and an opportunity to be heard.” Riccard v. Prudential Ins. Co., 307 F.3d 1277, 1296 (11th Cir. 2002). III. Analysis Defendants object to the Report and Recommendation on two grounds, which the Court will address in turn. A. Whether the CPI is Clear and Unambiguous Defendants argue that Judge Hoffman erred in finding that the CPI applies to USC’s hiring of Lane and USC’s subsequent use of the data Lane took from Nephron.4 As Judge Hoffman

noted, “Defendants do not dispute that the CPI was valid and lawful, or that they were able to comply with the CPI.” (Doc. 212 at 8). Therefore, the question here is whether the CPI is clear and unambiguous and whether its terms encompass Defendants’ conduct. Defendants contend that the CPI only prohibits their use of data that Hulsey took from Nephron.

4 Defendants do not raise any objections to Judge Hoffman’s factual findings or contend that Nephron failed to produce clear and convincing evidence that Defendants violated the CPI if it applies here. The Court agrees with Judge Hoffman’s findings on these points. The Court must interpret a consent decree, like the CPI here,5 “as [the Court] would a contract, applying principles of Florida’s general contract law.” Frulla v. CRA Holdings, Inc., 543 F.3d 1247, 1252 (11th Cir. 2008). The Court must construe any contract according to the parties’ intent and where the terms of a contract are unambiguous, “we must determine the parties’ intent from within the four corners of the contract.” Id. “A contract is ambiguous where it is susceptible

to two different interpretations, each one of which is reasonably inferred from the terms of the contract.” Id. (internal quotation marks omitted). The Court must first look to the language of the CPI. See Id. Subsection (a) of the CPI states that “Defendants shall not disclose, use, or communicate, in any manner whatsoever, either directly or indirectly, Nephron’s trade secrets or confidential business information including, but not limited to, the Protected IP.” (Doc. 29 at 3). The term “Protected IP” is defined in the CPI to mean “current and prospective customer lists and related databases, pricing data, purchasing histories, consumer data, market intelligence and strategies, product formulations and development information, proprietary manufacturing processes, and

overall industry and product expertise.” (Id. at 2 n.1). Subsection (j) of the CPI further states that “U.S. Compounding shall not, directly or indirectly, use any of Nephron’s trade secrets or confidential business information including, without limitation, the Protected IP in any manner including, without limitation, to solicit customers to do business with U.S. Compounding.” The CPI plainly states that Defendants are prohibited from using Nephron’s “Protected IP” “in any manner whatsoever.” The term “Protected IP” plainly encompasses the customer lists and pricing information that Lane took from Nephron and used in her employment with USC. Absent

5 This includes consent injunctions like the CPI. See F.T.C. v. Leshin, 618 F.3d 1221, 1231 (11th Cir. 2010) (quoting Sierra Club v. Meiburg, 296 F.3d 1021, 1029 (11th Cir. 2002)) (applying state contract law principles to interpret a stipulated injunction).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Nephron Pharmaceuticals Corporation v. Hulsey, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nephron-pharmaceuticals-corporation-v-hulsey-flmd-2021.